Plain-English Summary
SURMOUNT-4 is the tirzepatide maintenance counterpart to STEP 4: people who kept treatment generally maintained or extended weight loss, while those switched to placebo regained weight on average.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
75/100
Useful Public Evidence
- Evidence tier
- 78/100, weight 18%
- Design strength
- 89/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 68/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 45/100, weight 10%
- Publication/source strength
- 91/100, weight 10%
Useful for context, but limited by safety signal usefulness, endpoint relevance, limitations transparency.
How the study framework works ->Key Findings
- Participants lost substantial weight during the open-label tirzepatide lead-in before randomization.
- Continuing tirzepatide after the lead-in produced further average weight loss, while switching to placebo led to average weight regain.
- Most participants who continued tirzepatide maintained a large share of their prior weight loss, while most switched to placebo did not.
- The trial strongly supports the chronic-treatment framing for maintenance in medication responders.
Limitations
- Withdrawal design enriches for participants who tolerated and responded to tirzepatide during the lead-in.
- The study does not prove that every patient must stay on tirzepatide indefinitely.
- The trial does not answer affordability, access, long-term adherence, or off-ramp protocols.
Why It Matters
It gives the site a stronger, drug-class-level way to discuss weight regain after stopping incretin therapy rather than relying only on semaglutide data.
Viral Vitalism Verdict
Excellent maintenance evidence for responders, but not a simplistic forever-drug mandate.
Sources
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
VV Signal Score
76
Promising signal
- Sources
- 31
- Studies
- 11
- Claims
- 16
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
glp 1: Cost, access, adherence, tolerability, and long-term maintenance materially affect
Cost, access, adherence, tolerability, and long-term maintenance materially affect the real-world value of GLP-1 therapy.
glp 1: Weight maintenance commonly depends on continued treatment, while optimal
Weight maintenance commonly depends on continued treatment, while optimal long-term strategies and lean-mass preservation remain active evidence gaps.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
tirzepatide: Tirzepatide reduced body weight in adults with obesity or
Tirzepatide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
glp 1: GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level
GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level tolerability considerations.